Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Tradjenta (linagliptin) ## Overview Linagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus. It increases incretin levels, leading to enhanced insulin secretion and reduced glucagon secretion in a glucose-dependent manner. ## Primary Indications Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ## Adult Dosing The usual dose is 5 mg orally once daily. ## Pediatric Dosing Dosing has not been established in pediatric patients. ## Dose Adjustments No dose adjustment is necessary for patients with renal impairment or hepatic impairment. ## Contraindications * History of serious hypersensitivity reaction to linagliptin or any excipient in the formulation. * Use with a strong CYP3A4 inducer (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) may reduce linagliptin exposure and efficacy. ## Adverse Effects * **Serious:** Angioedema, anaphylaxis, severe skin reactions (e.g., Stevens-Johnson syndrome, rash, urticaria), pancreatitis, severe and disabling arthralgia. * **Common:** Nasopharyngitis, diarrhea. ## Key Drug Interactions * **CYP3A4 Inducers:** Rifampin, carbamazepine, phenytoin, and St. John's wort may decrease linagliptin efficacy. Monitor glycemic control closely and consider alternative antihyperglycemic agents. * **Other Antidiabetic Agents:** Increased risk of hypoglycemia when used in combination with sulfonylureas or insulin. Dose reduction of the sulfonylurea or insulin may be considered. ## Monitoring * **Primary:** Monitor glycemic control (HbA1c, fasting plasma glucose, postprandial glucose). * **Secondary:** Monitor for signs and symptoms of hypersensitivity reactions, pancreatitis, and severe skin reactions. ## Clinical Pearls * Linagliptin is not intended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. * Due to its minimal renal and hepatic excretion, linagliptin is a preferred option in patients with significant renal or hepatic impairment. * Patients should be advised to report any signs of allergic reaction or severe upper abdominal pain immediately to their healthcare provider. *** *Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols for complete and up-to-date guidance.*